Natera, Inc. (NASDAQ:NTRA) Experiences Heavy Trading Volume

0
21

Natera, Inc. shares had a trading volume of 400K in the last trading session. Trading volume was up 273.61% over the stocks average daily volume.

These funds have also shifted positions in (NTRA). As of quarter end Manufacturers Life Insurance Company, The had sold a total of 8,361 shares trimming its stake by 77.7%. The value of the company’s investment in Natera, Inc. went from $96,000 to $26,000 decreasing 72.9% quarter over quarter. As of the end of the quarter Renaissance Technologies LLC had acquired 47,500 shares growing its holdings by 11.5%. The value of the total investment in Natera, Inc. increased from $3,649,000 to $4,984,000 a change of 36.6% since the last quarter.

As of the end of the quarter Morgan Stanley had bought a total of 47,901 shares growing its position 31.7%. The value of the investment in Natera, Inc. went from $1,342,000 to $2,163,000 a change of $821,000 quarter to quarter. American International Group Inc augmented its stake by buying 3,413 shares an increase of 21.2%. American International Group Inc controls 19,478 shares valued at $212,000. The total value of its holdings increased 49.3%.

On August 7 Morgan Stanley kept the stock rating at “Overweight” but moved down the price target from $20.00 to $13.00.

The company is trading up by 2.65% since yesterday’s close of $11.34. Shares last traded at $11.64 much higher than $9.96, the 50 day moving average and which is significantly higher than the 200 day moving average of $9.64. The 50 day moving average was up $1.68 or +16.85% and the 200 day average was up $2.00.

In the last earnings report the EPS was $-2.43 and is expected to be $-2.03 for the current year with 53,223,000 shares presently outstanding. Analysts expect next quarter’s EPS will be $-0.36 with next year’s EPS projected to be $-1.02.

Natera, Inc., launched on January 26, 2007, is a diagnostics company. The Company is involved in the discovery, development and commercialization of genetic testing services. The Company operates a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) providing a host of preconception and prenatal genetic testing services..